The Regulatory Rule That Creates the Need for a US Sponsor of Record
Before any conversation about pricing, founders and regulatory affairs professionals need to understand the rule that makes a US Sponsor of Record legally necessary. Under 21 CFR 812.18(a), a sponsor of an Investigational Device Exemption (IDE) study must be located in the United States. A company headquartered outside the United States cannot itself hold the sponsor role for an FDA IDE study. A US person or entity must accept that legal responsibility and act as sponsor on record with the FDA. This single requirement is the reason non US device companies seeking US clinical data routinely engage a firm like ADB Consulting and CRO Inc. to fulfill the sponsor function.
The same principle applies regardless of device risk classification. Whether you are running a nonsignificant risk study under an abbreviated IDE pathway or a full IDE application under 21 CFR Part 812, the sponsor must be a US entity accountable to the FDA for regulatory submissions, adverse event reporting, and study oversight. Getting this structure wrong at the outset can delay study startup and trigger FDA deficiency letters that cost far more than the fee to establish proper sponsorship from day one.
Initiation Fee Versus Annual Fee: What ADB Charges
ADB Consulting and CRO Inc. publishes its US Sponsor of Record fee structure at adbccro.com/us-sponsor. According to ADB's published figures, the initiation fee is a one-time cost to establish the sponsor of record relationship, prepare the regulatory framework, and set up the compliance infrastructure required before a study begins. The ongoing annual fee covers the sponsor of record function across each year the study remains active and the IDE remains open.
What Is Not Included in ADB's Sponsor of Record Fee
Understanding exclusions is just as important as understanding what is covered. ADB's sponsor of record fee does not cover the following cost categories, which sponsors and device companies must budget for separately:
- Clinical site costs: Investigator agreements, site initiation payments, per-patient fees, and site management expenses are outside the scope of the sponsor of record engagement.
- CRO monitoring fees: Clinical research organization services for site monitoring visits, data management, and clinical operations are separate from the sponsor function and must be contracted independently.
- Clinical trial insurance: Liability and indemnification coverage for the study is the responsibility of the device company and is not included in the sponsor of record fee.
- IRB fees: Institutional Review Board submission fees, continuing review fees, and amendment fees are billed directly by the IRB and fall outside ADB's scope.
Keeping these line items clearly separated helps device companies build accurate study budgets and avoid surprises mid-study.
A Plain Checklist for Evaluating Any US Sponsor of Record Quote
If you are comparing multiple sponsor of record offers, use this checklist to assess each line item systematically. Generic quotes that omit any of these categories should prompt follow-up questions before you sign.
- Setup: Does the initiation fee include preparing the IDE regulatory framework, establishing the sponsor file, and reviewing protocol and investigator documentation? Confirm exactly what deliverables are covered before study start.
- Ongoing fee: Is the annual fee fixed or variable? Does it cover the full period the IDE remains open, and does it include regulatory correspondence with the FDA on sponsor-related matters?
- Submission support: Does the sponsor of record fee include preparing IDE supplements, annual progress reports under 21 CFR 812.150(b), and protocol amendment submissions? Clarify whether each submission type is included or billed separately.
- Monitoring: Is clinical site monitoring in scope or explicitly excluded? A sponsor of record firm is not automatically a CRO. Confirm who holds monitoring responsibility and how that handoff is documented.
- Safety reporting: Does the fee cover preparing and submitting IDE safety reports, including unexpected adverse device effects under 21 CFR 812.150(a)? Safety reporting is a core sponsor obligation and must be clearly addressed.
- Closeout: Is study closeout included in the annual fee or billed as a separate service? Closeout includes final FDA notifications and sponsor file archiving, which can generate additional work at study end.
Why the Sponsor of Record Structure Matters for Your Study Timeline
Device company leadership often focuses on IDE preparation costs and underestimates the ongoing compliance burden that comes with holding sponsor status. Under 21 CFR 812, the sponsor is responsible for selecting qualified investigators, monitoring the study, reviewing and evaluating adverse events, and maintaining accurate records. Delegating the sponsor of record role to an experienced US firm allows non US companies to meet these obligations without establishing a US legal entity, and allows US startups without regulatory infrastructure to fulfill sponsor duties correctly from study initiation through closeout.
ADB Consulting and CRO Inc. serves as the US Sponsor of Record for international and domestic medical device companies conducting FDA-regulated clinical studies under 21 CFR Part 812.
Reviewed October 23, 2026 by ADB's regulatory team.
Frequently Asked Questions
Can a non US company serve as the IDE sponsor if it has a US subsidiary?
A US subsidiary that is a legally distinct US entity may be able to hold the sponsor role, but this requires careful review of the subsidiary's legal structure, its ability to accept FDA regulatory accountability, and whether it has the internal infrastructure to fulfill all sponsor obligations under 21 CFR 812. Many companies find it more practical to engage an experienced sponsor of record firm rather than build that capacity internally within a newly formed subsidiary.
Does ADB's annual fee change if the study adds sites or expands enrollment?
Study scope changes such as additional investigational sites or protocol amendments may affect the scope of sponsor of record work. It is important to review ADB's engagement terms at adbccro.com/us-sponsor and discuss how scope changes are handled before you sign, so there are no billing surprises when your study grows.
What happens to the sponsor of record relationship when the IDE study closes?
When the IDE is closed, the sponsor of record has final obligations including notifying the FDA and investigators, preparing the closeout report, and archiving study records. Confirm with any sponsor of record firm whether closeout activities are included in the annual fee or assessed as a separate engagement phase, and what record retention obligations the sponsor of record firm will fulfill on your behalf after study end.
Ready to Assess Your US Sponsor of Record Options?
If you are preparing for an FDA IDE study and need to assess your US sponsorship structure, ADB Consulting and CRO Inc. is ready to review your program and help you understand exactly what a sponsor of record engagement would cover for your specific study design. Visit adbccro.com/us-sponsor to review published fee information, then book a free discovery call with Andre Butler and the ADB regulatory team to discuss your study timeline, budget, and regulatory pathway.
For related guidance, see our US Sponsor of Record service.
Ready to Navigate the FDA Process with Confidence?
Book a free 30-minute discovery call with ADB's regulatory team to discuss your specific device and situation.
Book a Free Pathway Call